Decision: Favourable
Study Title:
A Phase 2b Randomized, Double-blind, Active- and Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease
NREC Code:
23-NREC-CT-018
Decision:
Favourable
Meeting Date:
24/05/2023
Study Type:
CT application
Principal Investigator:
Professor Laurence Egan
PI Institution:
University Hospital Galway
Sponsor:
Janssen-Cilag International NV